Cybin Inc. has announced a registered direct offering of 22,277,750 common shares and pre-funded common share purchase warrants priced at US$6.51 per share, generating aggregate gross proceeds of US$175,009,911.45. The financing attracted participation from both new and existing institutional investors including Venrock Healthcare Capital Partners, OrbiMed, Point72, Deep Track Capital, and several other prominent healthcare investment firms.
Each share or pre-funded warrant in the offering includes 0.35 of one common share purchase warrant exercisable at US$8.14 per share. These warrants remain valid until the earliest of three conditions: June 30, 2027; 30 days after topline data release for the APPROACH trial of CYB003 in major depressive disorder; or 30 days following an acceleration notice if the NYSE American closing price equals or exceeds US$19.53 for five consecutive trading days. The full details of the offering are available in the company's official press release at https://ibn.fm/TPxvo.
This substantial capital infusion represents a critical milestone for Cybin, a late-stage neuropsychiatry company focused on revolutionizing mental healthcare through novel treatment development. The company's current pipeline includes CYB003, a proprietary deuterated psilocin analog that has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration and is currently in Phase 3 studies for adjunctive treatment of major depressive disorder. Additionally, Cybin is developing CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule in Phase 2 studies for generalized anxiety disorder.
The significance of this financing extends beyond corporate growth to address substantial public health challenges. Mental health conditions represent one of the largest unmet medical needs globally, with current treatment options often providing inadequate relief for many patients. Cybin's approach focuses on developing next-generation psychedelic-derived treatments that may offer more effective and durable results compared to existing antidepressants and anti-anxiety medications.
The involvement of multiple established healthcare investment firms signals growing confidence in the potential of psychedelic-based therapies within mainstream medicine. This funding will enable Cybin to advance its clinical programs through critical late-stage development, potentially bringing new treatment options to millions suffering from treatment-resistant mental health conditions. Investors and stakeholders can follow the company's progress through its newsroom at https://ibn.fm/CYBN.
The timing of this financing coincides with increasing recognition within the medical community that novel approaches are needed to address the limitations of current mental health treatments. As research into psychedelic-assisted therapies gains scientific credibility and regulatory acceptance, companies like Cybin are positioned to potentially transform how depression and anxiety are treated. The successful completion of this substantial offering demonstrates the investment community's belief in both the scientific validity of Cybin's approach and the commercial potential of psychedelic-based medicines.
